8-K: IN8bio Director Resigns, Interim Chair Appointed
Corporate Governance Update
IN8bio, Inc. announced the resignation of director Alan S. Roemer and the appointment of Jeremy Graff as Interim Chair of the Board, effective February 28, 2026.
Summary
- Alan S. Roemer notified the Board of Directors of IN8bio, Inc. of his decision to resign as a director and as a member of the Audit and Compensation Committees.
- Mr. Roemer's resignation is effective as of February 28, 2026.
- His decision was not the result of any disagreement with the Company, its management, the Board, or any committees thereof.
- The Board has appointed Jeremy Graff, an independent director, as Interim Chair of the Board, effective as of February 28, 2026.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The amicable nature of the resignation and prompt appointment of an independent interim chair suggest stable corporate governance, avoiding potential negative interpretations of a director departure.
Positives
- The resignation of Alan S. Roemer was explicitly stated not to be due to any disagreement with the company, management, or the Board, suggesting a smooth transition.
- The Board promptly appointed an independent director, Jeremy Graff, as Interim Chair, ensuring continuity in leadership.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that changes in board composition, particularly the appointment of an interim chair, are common events in the biotechnology sector, often reflecting evolving strategic needs or director availability. The explicit statement of no disagreement is a positive signal, differentiating it from situations where resignations might indicate underlying issues.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director, Audit Committee Member, Compensation Committee Member | Alan S. Roemer | NA | 2026-02-28 | Resignation |
| Interim Chair of the Board | NA | Jeremy Graff | 2026-02-28 | Appointment |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Composition Change | Alan S. Roemer resigned as a director and from the Audit and Compensation Committees. | 2026-02-28 | Reduces the number of independent directors by one, but the prompt appointment of an independent interim chair maintains leadership structure. |
| Leadership Appointment | Jeremy Graff, an independent director, was appointed as Interim Chair of the Board. | 2026-02-28 | Ensures continuity in board leadership with an independent director at the helm. |
Stakeholder Impact
- Shareholders: The amicable nature of the director's departure and the prompt appointment of an interim chair may reassure shareholders about board stability.
- Employees: Unlikely to have a direct impact on day-to-day operations or employee morale.
Key Dates
| Date | Description |
|---|---|
| 2026-02-26 | Date of earliest event reported: Alan S. Roemer notified the Board of his decision to resign. |
| 2026-02-27 | Date the 8-K report was signed by William Ho. |
| 2026-02-28 | Effective date of Alan S. Roemer's resignation and Jeremy Graff's appointment as Interim Chair. |
Recommendation
holdThe filing details a routine corporate governance change involving a director's amicable resignation and the appointment of an interim board chair. This event does not present new information that would fundamentally alter the company's financial outlook or strategic direction, thus a 'hold' recommendation is appropriate as existing investment theses remain unchanged.
Keywords
IN8bio, INAB, Board of Directors, Director Resignation, Corporate Governance, Interim Chair, Management Change, SEC Filing, 8-K
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.